Carboprost

Administration

• Type: Uterotonic
• Dosage Forms: 250 mcg/mL
• Routes of Administration: IV, IM
• Common Trade Names: Hemabate

Adult Dosing

Postpartum hemorrhage

• 250 mcg IM x1
  • May repeat q15-90min for refractory bleeding
  • Max 2mg total dose

Pediatric Dosing

• Pediatric dosing not applicable or safety has not been established in pediatric patients.

Special Populations

Pregnancy Rating

• Avoid use in 3rd trimester
• Possible risk of embryo-fetal toxicity

Lactation risk

• Caution advised when breastfeeding

Renal Dosing

• Adult: Contraindicated in acute impairment
• Pediatric: N/a

Hepatic Dosing

• Adult: Contraindicated in acute impairment
• Pediatric: N/a

Contraindications

• Allergy to class/drug
• Hypersensitivity to prostaglandin
• PID, acute
• Acute renal impairment
• Acute pulmonary disease
• Acute hepatic disease
• CAD
• Caution if asthma

Adverse Reactions

Serious

• Uterine rupture
• Hemorrhage, hematemesis
• Respiratory distress, pulmonary edema

Common

• vomiting, nausea, diarrhea
• fever, flushing
• HTN
• Cough, headache, pain, bronchospasm

Pharmacology

• Half-life: Unknown
• Metabolism: Liver primarily, lung
• Excretion: Urine (<1% unchanged)

Mechanism of Action

• Stimulates smooth muscle and uterine contractions
• Acts as synthetic prostaglandin

See Also

• Postpartum hemorrhage